Most health insurance plans in the United States do cover BRCA genetic testing, but whether you personally qualify for covered testing depends on your insurance type, your personal and family medical history, and which clinical criteria your insurer uses. Under the Affordable Care Act, private insurers must cover BRCA risk assessment, genetic counseling, and testing without cost-sharing for women who meet specific risk criteria. The reality on the ground, though, is messier than that blanket statement suggests, with meaningful gaps in Medicare, wide variation across state Medicaid programs, and a surprising number of prior authorization requests that get denied.
What the ACA Actually Requires
The foundation for insurance coverage of BRCA testing in the private market rests on a recommendation from the U.S. Preventive Services Task Force. The USPSTF recommends that primary care clinicians screen women who have a personal or family history of breast, ovarian, tubal, or peritoneal cancer, or who have ancestry associated with BRCA1/2 mutations, using a brief risk assessment tool. Women who screen positive should then receive genetic counseling and, if counseling indicates it, genetic testing.1U.S. Preventive Services Task Force. Recommendation: BRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic Testing Because the ACA requires private insurers to cover USPSTF “A” and “B” grade recommendations with no out-of-pocket cost, this effectively means that if you have a non-grandfathered private health plan and you meet the risk criteria, the test should be free to you.
That word “should” is doing real work, though. The mandate applies to the testing pathway as a whole: risk assessment first, then counseling, then testing if indicated. Skip or rearrange the steps and your insurer may not cover it. Some insurers also require that genetic counseling be provided by a certified genetic counselor specifically, which can create an access bottleneck in areas where those specialists are scarce.2BioMed Central / Springer Nature (BMC Health Services Research). Impact of a genetic counseling requirement prior to genetic testing
Who Qualifies for Covered Testing
The coverage mandate does not mean anyone can walk into a clinic and get a free BRCA test. Eligibility hinges on risk factors. Common criteria that private insurers look for include a personal history of breast or ovarian cancer diagnosed at a young age, multiple relatives on the same side of the family with breast or ovarian cancer, a known BRCA mutation in a close relative, male breast cancer in the family, and Ashkenazi Jewish or other ancestry groups with elevated carrier rates. Family history of breast and ovarian cancer is a primary criterion for coverage eligibility among private payers.3Genetics in Medicine. Eligibility criteria in private and public coverage policies for BRCA genetic testing and genetic counseling
If you do not have any of these risk factors, your insurer is unlikely to cover the test. This is where people often feel frustrated: you might be worried about your risk, but worry alone is not a clinical criterion. The USPSTF explicitly does not recommend routine screening for the general population of women who lack risk indicators, and insurers follow that guidance closely.
Medicare’s Narrower Rules
Medicare takes a more restrictive approach than most private plans. While private insurers generally cover testing for people both with and without a personal cancer diagnosis (as long as family history criteria are met), Medicare’s local coverage determinations have historically limited BRCA testing to people who already have a cancer diagnosis. A local Medicare carrier policy in Washington State stated explicitly that “screening services, such as presymptomatic genetic tests and services” are not a Medicare benefit, and that family history without a personal history of cancer is not adequate for Medicare coverage.3Genetics in Medicine. Eligibility criteria in private and public coverage policies for BRCA genetic testing and genetic counseling
This creates a genuine gap. If you are on Medicare and have a strong family history of BRCA-related cancers but have not been diagnosed yourself, you may find that Medicare will not pay for testing. The logic from Medicare’s perspective is that it covers diagnostic services, not screening, but from a cancer prevention standpoint the distinction is counterproductive. Identifying a BRCA mutation before cancer develops is the whole point of genetic testing for high-risk individuals.
Medicaid Varies Dramatically by State
Medicaid coverage for BRCA testing is a patchwork. The situation has improved substantially since the ACA, with nearly every state’s Medicaid program now covering BRCA genetic counseling and testing in some form. Only Alabama does not cover genetic testing for hereditary cancer risk at all.4PubMed Central. Medicaid Expansions: Probing Medicaid’s Filling of the Cancer Genetic Testing and Screening Space But the details matter enormously. Some state Medicaid programs follow the Medicare model, covering testing only for people who already have a cancer diagnosis and not for unaffected relatives with a family history.
A 2024 analysis of all 50 state Medicaid plans found that only about 58% explicitly or implicitly cover testing that aligns with current national clinical guidelines. Of the states that fell short, the vast majority were referencing outdated guideline criteria, suggesting a lag in updating their policies rather than a deliberate choice to exclude patients.5PubMed. Medicaid Coverage of NCCN- and ASCO/SSO-Guideline-Concordant BRCA Germline Testing for Patients with Breast Cancer: Opportunity to Embrace Rapid Advancements in Precision Medicine Only one state, Colorado, covered the newer guideline-concordant BRCA testing for all newly diagnosed breast cancer patients. The practical effect is that people on Medicaid in some states face the same barriers as Medicare beneficiaries, while those in other states have access comparable to private insurance.
Prior Authorization and Denied Requests
Even when your insurance technically covers BRCA testing, you may need prior authorization before the test is performed. This is where coverage can break down in practice. An analysis of preauthorization requests submitted to one major insurer found that roughly 22% of requests did not meet criteria. About a quarter of those denied requests involved situations where the patient’s clinical history actually suggested testing for a different cancer syndrome or indicated that a different family member should be tested first.6PubMed. Analysis of insurance preauthorization requests for BRCA1 and BRCA2 genetic testing: experience of the Humana Genetic Guidance Program
That 22% figure is worth sitting with. It means that in roughly one out of five cases, the ordering clinician thought testing was warranted but the insurer disagreed. Sometimes the denial is appropriate, perhaps the criteria genuinely were not met or a different test was more suitable. But it also means patients and providers regularly encounter friction. If you receive a denial, you can appeal, and understanding why the denial occurred (wrong criteria, wrong family member, or incomplete documentation) helps you build a stronger appeal.
Multigene Panels Face Steeper Hurdles
BRCA1 and BRCA2 are the best-known cancer susceptibility genes, but they are not the only ones. Today, many labs offer multigene panels that test for dozens of genes linked to hereditary cancer risk in a single run. These panels can be clinically useful, but insurance coverage for them is much spottier than for standalone BRCA testing. A study of payer policies found that while most insurers had coverage policies that specifically addressed multigene panels, none provided positive coverage outright. Most, about 77%, classified panels as investigational or experimental. The rest limited coverage to panels where every gene on the panel was individually considered medically necessary.7PubMed Central. Availability and payer coverage of BRCA1/2 tests and gene panels
This means that if your doctor orders a broad multigene panel instead of isolated BRCA1/2 testing, your insurer may cover the BRCA portion but deny the rest, or deny the entire panel. This is evolving as clinical guidelines increasingly support panel testing, but coverage policies tend to lag behind the science by several years. If cost is a concern, ask your provider whether standalone BRCA testing would be sufficient for your situation before defaulting to a broader panel.
Cascade Testing for Family Members
When someone tests positive for a BRCA mutation, their close relatives have a meaningful chance of carrying the same variant. Testing those family members is called cascade testing, and it is both medically straightforward and relatively inexpensive, since labs only need to check for the specific known variant rather than sequencing the full genes. A study using commercial claims data identified hundreds of families where a proband (the first person tested) was followed by cascade testers on the same insurance plan. Cascade testers were more likely to have genetic counseling before testing and more likely to receive a targeted known-variant test, both of which align with clinical guidelines.8PubMed Central. Use of Family Relationships in Commercial Claims Data to Characterize Clinical Events of Patients with BRCA1/2 Cascade Testing
Most private insurers cover cascade testing when there is a documented known mutation in the family, and it typically costs far less than the initial comprehensive test. The barrier is often practical rather than financial: getting family members to actually follow through. If you have tested positive for a BRCA mutation, encouraging your siblings, children, and other close relatives to get cascade testing is one of the most impactful things you can do. The test itself is simpler, faster, and almost always covered.
What Testing Actually Costs Out of Pocket
The sticker price of BRCA testing has dropped substantially over the past decade. Comprehensive BRCA testing costs fell by about 68% from 2013 to 2022 among privately insured adults, and most people who had the test during that period paid nothing out of pocket.9PubMed. BRCA genetic testing utilization and expenditures among privately insured adults in the United States, 2013 to 2022 The end of Myriad Genetics’ patent monopoly on BRCA testing in 2013, following a Supreme Court decision, opened the market to competing laboratories and drove prices down considerably.
For people without insurance or whose insurance does not cover the test, several lab companies offer financial assistance programs or flat-rate self-pay pricing, often in the range of a few hundred dollars. That is still a meaningful cost for low-income patients, but it is a fraction of what the same test would have cost a decade ago. A study at a safety-net institution found that among patients referred for genetic cancer risk assessment, about two-thirds lacked health insurance entirely, yet the vast majority who were offered testing agreed to it, suggesting that when financial assistance is available, cost does not have to be the barrier it once was.10Springer Link / PubMed Central. Participation of low-income women in genetic cancer risk assessment and BRCA 1/2 testing: the experience of a safety-net institution
Grandfathered Health Plans Are the Hidden Gap
There is one category of private insurance that is exempt from the ACA’s preventive services mandate: grandfathered health plans. These are plans that were in place before March 23, 2010, and have not made significant changes to their benefits or cost structures since then. If your employer-sponsored plan is grandfathered, it is not required to cover BRCA risk assessment, counseling, or testing at no cost, even if you meet every clinical criterion.11Oxford Academic (Journal of Law and the Biosciences). Prevention for those who can pay: insurance reimbursement of genetic-based preventive interventions in the liminal state between health and disease The plan may still choose to cover it, but it is not legally obligated to do so without cost-sharing.
Grandfathered plans have been declining in number year by year as employers update their plans, but they still cover a notable slice of the privately insured population. If you are unsure whether your plan is grandfathered, check your plan documents or call your insurer directly. This is one of the first things to verify before assuming your BRCA test will be free.
What Happens After a Positive Result
Coverage of the test itself is only part of the story. People who test positive for a BRCA1 or BRCA2 mutation face decisions about enhanced surveillance (more frequent mammograms, breast MRIs, ovarian cancer screening) and risk-reducing surgeries like prophylactic mastectomy or oophorectomy. The good news is that insurance generally covers these procedures. In one study of patients with confirmed BRCA mutations, 97% of risk-reducing surgeries were reimbursed in full, less the normal coinsurance and deductibles. Only a single patient was denied, and the researchers found no significant differences in reimbursement rates based on type of insurance, personal cancer history, or type of procedure.12Genetics in Medicine. Insurance reimbursement for risk-reducing mastectomy and oophorectomy in women with BRCA1 or BRCA2 mutations
However, formal coverage policies for prophylactic surgery have not been universal. An earlier survey found that only about 44% of private plans had specific policies for prophylactic mastectomy in cases of strong family history, and the figure was even lower for prophylactic oophorectomy. Government carriers were significantly less likely to have any policy for prophylactic surgery at all.13PubMed. Current national health insurance coverage policies for breast and ovarian cancer prophylactic surgery Not having a specific policy does not always mean the procedure is denied, since individual case review may approve it, but it does create uncertainty and potential delays.
Genetic Discrimination Protections and Their Limits
One concern that keeps people from pursuing BRCA testing is fear that a positive result could be used against them by insurers. The Genetic Information Nondiscrimination Act, commonly known as GINA, provides meaningful but incomplete protection. GINA prohibits health insurers from using genetic information to deny coverage, raise premiums, or impose pre-existing condition exclusions. It also bars employers from using genetic information in hiring, firing, or promotion decisions. For health insurance and employment purposes, your BRCA status is legally protected.
The gap is significant, though. GINA does not apply to life insurance, long-term care insurance, or disability insurance.14PubMed Central. Beyond the Genetic Information Nondiscrimination Act: ethical and economic implications of the exclusion of disability, long-term care and life insurance A life insurer can legally ask about your genetic test results and use them when setting premiums or deciding whether to issue a policy. Some genetic counselors advise patients to secure life and disability insurance before undergoing BRCA testing, though the ethics of this advice are debated. A few states have passed their own laws extending genetic nondiscrimination protections to life and disability insurance, but most have not.
The Push Toward Population-Wide Testing
Current coverage models are built around the idea that only people with a suspicious personal or family history should be tested. But research increasingly suggests that this family-history-based approach misses a lot of mutation carriers. Many people who carry BRCA variants have no known family history of cancer, either because the family is small, because relevant relatives died of other causes before cancer could develop, or because family medical information is simply unavailable.
Economic evaluations have found that testing all women in a given population for BRCA mutations, rather than only those with family history flags, is cost-effective. A 2024 modeling study estimated that population-based BRCA testing in Canada could prevent over 2,500 breast cancers and nearly 500 ovarian cancers per million women tested, averting hundreds of cancer deaths. The cost per quality-adjusted life year gained was well below standard willingness-to-pay thresholds, remaining cost-effective for women tested between ages 30 and 60.15JAMA Network Open. Economic Evaluation of Population-Based BRCA1 and BRCA2 Testing in Canada A systematic review of economic evaluations also confirmed that population-based testing compared favorably to family-history-based testing across multiple study designs.16PubMed Central. Population or family history based BRCA gene tests of breast cancer? A systematic review of economic evaluations
If policy eventually catches up to this evidence, BRCA testing coverage could shift from a gatekept benefit for high-risk individuals to a routine screen offered to a much broader population. That shift has not happened yet, and it would require a change in USPSTF recommendations or new legislative action to trigger a coverage mandate. But it is the direction the health economics evidence is pointing, and several pilot programs around the world are testing what population-level BRCA screening looks like in practice.
Men and BRCA Testing
BRCA mutations are often framed as a women’s health issue, but men carry and pass on these mutations too, and male carriers face their own elevated cancer risks, including prostate cancer, pancreatic cancer, and male breast cancer. Coverage for men who meet risk criteria has generally followed the same rules as for women: if you have the right family history or personal cancer history, private insurance should cover testing. In practice, though, awareness among both patients and primary care providers that men should be assessed for BRCA risk is lower, and referrals for men happen less often. The overall decline in testing costs has at least removed some financial barriers: median expenditures for comprehensive BRCA testing dropped substantially over the past decade, with most privately insured individuals paying nothing out of pocket regardless of sex.9PubMed. BRCA genetic testing utilization and expenditures among privately insured adults in the United States, 2013 to 2022
Direct-to-Consumer Tests Are Not the Same Thing
Companies like 23andMe offer a limited BRCA screening as part of their consumer genetic testing kits, but these products test for only a handful of the most common BRCA variants, primarily those prevalent in people of Ashkenazi Jewish descent. They do not sequence the full BRCA1 and BRCA2 genes and will miss the vast majority of pathogenic mutations. A negative result from a consumer test does not mean you do not carry a BRCA mutation.
Insurance does not typically cover direct-to-consumer genetic tests, nor would there be reason for it to. Clinical BRCA testing, ordered through a healthcare provider and performed by a certified laboratory, remains the standard for making medical decisions. If a direct-to-consumer test flags a BRCA variant, the recommended next step is confirmatory clinical-grade testing through your doctor, which then follows the normal insurance coverage pathways described above. The consumer test can be a useful prompt to seek clinical evaluation, but it is not a substitute for it.